Vista Partners Initiates Coverage on Mount TAM Biotechnologies, Inc. (Ticker: MNTM); $3.25 Price Target
Vista Partners has initiated coverage on Mount TAM Biotechnologies, Inc. (OTCBB: MNTM) (“The Company,” or “MNTM”) with a twelve-month price target of $3.25. Ross Silver, Principal Analyst at Vista Partners, stated, “Mount Tam’s first and most advanced product (TAM-01), was acquired through a licensing agreement with The Buck Institute for Research on Aging. TAM-01 is intended for the treatment of systemic lupus erythematosus (“SLE”), the most common form of lupus and is the Company’s lead compound.” Mr. Silver concludes, “According to the Lupus Foundation of America, 1.5 million Americans have some form of lupus and more than 16,000 new cases are reported annually in the United States alone, while other estimates are more conservative. TAM-01 is small molecule that in preclinical animal models has shown the potential to be disease modifying and has the potential to treat lupus nephritis, as a reminder 60% of SLE patients have lupus nephritis.”
To download a FREE copy of the Mount TAM Biotechnologies, Inc. research report, please visit http://www.vistapglobal.com and click the “download research” icon to gain access to the report. The iShares Nasdaq Biotechnology (Nasdaq: IBB) is down almost 25% in 2016.
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista’s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Disclaimer & Disclosure: